DOI: https://doi.org/10.36347/sjmcr.2026.v14i04.059

Pages: 833-841

Anthracycline-induced cardiotoxicity is a significant and dose-dependent complication in cancer patients, associated with heart failure and high morbidity and mortality. Its pathophysiology includes oxidative stress, mitochondrial damage, apoptosis, and alterations in iron metabolism, which impair myocardial contractility. It can manifest acutely, early, or late, with the latter being the most frequent. Early diagnosis relies on biomarkers such as BNP and troponins, along with imaging studies. Prevention includes limiting the cumulative dose and using dexrazoxane. Treatment with ACE inhibitors and bisoprolol improves cardiac function and clinical prognosis. In this article, we review the response to bisoprolol treatment for heart failure in six hematological patients with post-chemotherapy cardiotoxicity, who underwent follow-up transthoracic echocardiograms and had their response assessed by B-type natriuretic peptide levels for at least four weeks.